Sandbox/00030: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with " {| style="border: 2px solid #A8A8A8; font-size: 90%;" ! align="center" style="background: #A8A8A8;" | '''Clinical Manifestation''' ! align="center" style="background: #A8A8...")
 
mNo edit summary
Line 1: Line 1:


{| style="border: 2px solid #A8A8A8; font-size: 90%;"
{| style="border: 2px solid #A8A8A8; font-size: 90%;"
! align="center" style="background: #A8A8A8;" | '''Clinical Manifestation'''
! align="center" style="background: #A8A8A8; padding: 0 10px;" colspan=2 | '''Site of Infection, by Severity or Extent'''
! align="center" style="background: #A8A8A8; padding: 0 10px;" | '''PEDIS Grade'''
! align="center" style="background: #A8A8A8; padding: 0 10px;" | '''Route of Administration'''
! align="center" style="background: #A8A8A8; padding: 0 10px;" | '''IDSA Severity'''
! align="center" style="background: #A8A8A8; padding: 0 10px;" | '''Setting'''
! align="center" style="background: #A8A8A8; padding: 0 10px;" | '''Duration of Therapy'''
|-
|-
| style="background: #DCDCDC; padding: 0 10px;" | '''No symptoms or signs of infection'''
! style="background: #DCDCDC; padding: 0 10px;" rowspan=3 | '''Soft-tissue only'''
! style="background: #DCDCDC; padding: 0 10px;" | 1
| style="background: #DCDCDC; padding: 0 10px; font-weight: bold;" | Mild (Grade 2)
! style="background: #DCDCDC; padding: 0 10px;" | Uninfected
| style="background: #DCDCDC; padding: 0 10px;" | Oral (or topical for superficial infections)
| style="background: #DCDCDC; padding: 0 10px;" | Outpatient
| style="background: #DCDCDC; padding: 0 10px; text-align: center;" | 1–2 wk
|-
|-
| style="background: #F5F5F5; padding: 0 10px;" | '''Local infection involving only the skin and the subcutaneous tissue''' <u>without</u> involvement of deeper tissues and <u>without</u> signs of SIRS
| style="background: #DCDCDC; padding: 0 10px; font-weight: bold;" | Moderate (Grade 3)
* If erythema, must be >0.5 cm to ≤2 cm around the ulcer.
| style="background: #DCDCDC; padding: 0 10px;" | Oral (or initial parenteral)
* Exclude other causes of an inflammatory response of the skin (eg, trauma, gout, acute Charcot neuro-osteoarthropathy, fracture, thrombosis, venous stasis).
| style="background: #DCDCDC; padding: 0 10px;" | Outpatient (or inpatient)
! style="background: #F5F5F5; padding: 0 10px;" | 2
| style="background: #DCDCDC; padding: 0 10px; text-align: center;" | 1–3 wk
! style="background: #F5F5F5; padding: 0 10px;" | Mild
|-
|-
| style="background: #DCDCDC; padding: 0 10px;" | '''Local infection with erythema >2 cm or involving structures deeper than skin and subcutaneous tissues (eg, abscess, osteomyelitis, septic arthritis, fasciitis)''' <u>without</u> signs of SIRS
| style="background: #DCDCDC; padding: 0 10px; font-weight: bold;" | Severe (Grade 4)
! style="background: #DCDCDC; padding: 0 10px;" | 3
| style="background: #DCDCDC; padding: 0 10px;" | Initial parenteral, switch to oral when possible
! style="background: #DCDCDC; padding: 0 10px;" | Moderate
| style="background: #DCDCDC; padding: 0 10px;" | Inpatient, then outpatient
| style="background: #DCDCDC; padding: 0 10px; text-align: center;" | 2–4 wk
|-
|-
| style="background: #F5F5F5; padding: 0 10px;" | '''Local infection with the signs of SIRS''', as manifested by ≥2 of the following:
! style="background: #F5F5F5; padding: 0 10px;" rowspan=4 | '''Bone or joint'''
* Temperature &gt;38 °C or &lt;36 °C
| style="background: #DCDCDC; padding: 0 10px; font-weight: bold;" | No residual infected tissue
* Heart rate &gt;90 beats/min
| style="background: #F5F5F5; padding: 0 10px;" | Parenteral or oral
* Respiratory rate &gt;20 breaths/min or PaCO2 &lt;32 mm Hg
| style="background: #F5F5F5; padding: 0 10px;" | Inpatient, then outpatient
* White blood cell count &gt;12,000 or &lt;4,000 cells/μL or ≥10% immature (band) forms
| style="background: #F5F5F5; padding: 0 10px; text-align: center;" | 2–5 d
! style="background: #F5F5F5; padding: 0 10px;" | 4
|-
! style="background: #F5F5F5; padding: 0 10px;" | Severe
| style="background: #DCDCDC; padding: 0 10px; font-weight: bold;" | Residual infected soft tissue
| style="background: #F5F5F5; padding: 0 10px;" | Parenteral or oral
| style="background: #F5F5F5; padding: 0 10px;" | Inpatient, then outpatient
| style="background: #F5F5F5; padding: 0 10px; text-align: center;" | 1–3 wk
|-
| style="background: #DCDCDC; padding: 0 10px; font-weight: bold;" | Residual infected, viable bone
| style="background: #F5F5F5; padding: 0 10px;" | Initial parenteral, switch to oral when possible
| style="background: #F5F5F5; padding: 0 10px;" | Inpatient, then outpatient
| style="background: #F5F5F5; padding: 0 10px; text-align: center;" | 4–6 wk
|-
| style="background: #DCDCDC; padding: 0 10px; font-weight: bold;" | Residual dead bone or no surgery
| style="background: #F5F5F5; padding: 0 10px;" | Initial parenteral, switch to oral when possible
| style="background: #F5F5F5; padding: 0 10px;" | Inpatient, then outpatient
| style="background: #F5F5F5; padding: 0 10px; text-align: center;" | ≥3 mo
|}
|}

Revision as of 15:24, 3 June 2014

Site of Infection, by Severity or Extent Route of Administration Setting Duration of Therapy
Soft-tissue only Mild (Grade 2) Oral (or topical for superficial infections) Outpatient 1–2 wk
Moderate (Grade 3) Oral (or initial parenteral) Outpatient (or inpatient) 1–3 wk
Severe (Grade 4) Initial parenteral, switch to oral when possible Inpatient, then outpatient 2–4 wk
Bone or joint No residual infected tissue Parenteral or oral Inpatient, then outpatient 2–5 d
Residual infected soft tissue Parenteral or oral Inpatient, then outpatient 1–3 wk
Residual infected, viable bone Initial parenteral, switch to oral when possible Inpatient, then outpatient 4–6 wk
Residual dead bone or no surgery Initial parenteral, switch to oral when possible Inpatient, then outpatient ≥3 mo
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox/00030&oldid=975249"